Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Labeling compliance burden comments sought

This article was originally published in The Tan Sheet

Executive Summary

Roughly 500 nonprescription drugs introduced annually through new drug applications or abbreviated NDAs must comply with FDA's standardized format and content requirements for labeling marketed OTC drug products. In a June 3 Federal Register notice seeking comments on a proposed collection of information on industry's burden for compliance with the 1999 OTC labeling final rule, FDA says the Consumer Healthcare Products Association provided data for the estimate. The notice also says some 4,750 OTC sunscreen stock-keeping units have not complied with the labeling rule, but need to by a date the agency will set when it publishes a final rule for the OTC sunscreen monograph. FDA estimates firms need five hours to prepare labeling for OTC NDAs and ANDAs and two hours for sunscreen labeling prior to submitting the information to the agency. Monograph OTC drugs already must comply with the labeling rule. The deadline for comments is Aug. 3

You may also be interested in...

EU’s SCCS Finds Endocrine-Disrupting Evidence Inconclusive In UV Filter Reassessments

While endocrine-disrupting evidence was inconclusive, the Scientific Committee on Consumer Safety recommends more conservative limits on use of homosalate, octocrylene and benzophenone-3 in cosmetic products compared with current requirements under the European Cosmetics Product Regulation.

US FDA Urges COVID-19 Transmission Risk Mitigation In Cell And Gene Therapy Manufacturing

The risk of inadvertently growing SARS-CoV-2 virus in cell and gene therapies and possibly infecting patients and workers should be assessed and mitigated, the agency advises.

COVID-19: US Acted To Beat Other Countries To Next 1.25M Doses Of Regeneron Cocktail

Move was meant to preempt others’ efforts to secure the next six months of Regeneron’s COVID-19 antibody therapeutic.





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts